Pasireotide Injection and Alogliptin: Interaction Details

Brand names
Alogliptin
Nesina
Pasireotide Injection
SigniforSignifor LAR
Dr. Brian Staiger, PharmD, BCPS

Medically reviewed by ⁠

Also reviewed by the HelloPharmacist Editorial Team Updated AI-assisted Details about this page

A close look at the Pasireotide Injection and Alogliptin interaction:

Share

Share this interaction

Pasireotide Injection

Brand names
  • Signifor
  • Signifor LAR

What Happens When You Take Pasireotide Injection With Alogliptin

What can happen when they are taken together (rated Major)

An increased risk of and impaired glucose regulation

Interaction Deep Dive

A note from Dr. Brian Staiger If you’re a patient, this deep dive may be too technical, or bore you (or both). Read the plain-language explanation →

Insulin and glucagon secretion are both suppressed by somatostatin analogs.2 This can lead to marked rises in blood glucose.

In patients whose diabetes is poorly controlled, antidiabetic therapy should be optimized before the somatostatin analog is initiated.1 The antidiabetic agent may need a dose adjustment, and glucose should possibly be monitored more often.345

The Pasireotide Injection and Alogliptin Interaction, Explained

Pasireotide can change how your body controls blood sugar, and alogliptin is a diabetes medicine meant to keep it steady. Pasireotide slows the release of insulin and glucagon, the hormones that balance your sugar. Your records list this as a risk of both low blood sugar and unstable blood sugar control. The main concern with pasireotide is that blood sugar can rise sharply. This is based on how the drugs are expected to work, not on proven reports of harm in people taking both.

Keep taking both as prescribed. Your pharmacist or doctor may check your blood sugar more often and may adjust your diabetes treatment to suit you. Tell them about any shakiness, sweating, confusion, extreme thirst, or frequent urination.

Mechanism: Pasireotide, a somatostatin analog, suppresses insulin and glucagon secretion ( effect on glucose homeostasis). Alogliptin is a DPP-4 that enhances incretin-mediated insulin secretion. No interaction is described.

  • Effect: Impaired glucose regulation; severe is the principal labeled risk, and the database also lists risk. Pasireotide may blunt the of alogliptin.
  • Onset: Unspecified. Evidence: Theoretical. Severity on file: Major.
  • Management: Optimize antidiabetic therapy before starting pasireotide in poorly controlled diabetes. Increase the frequency of glucose monitoring. Individualize and adjust the antidiabetic dose as needed.

See the 5 references behind this explanation ↓

From the HelloPharmacist Pharmacy Team

AI-assisted: written with AI from this pair’s record in our interaction database, and reviewed by the HelloPharmacist pharmacy team. Written .

How we build these pages · How we use AI · Our editorial policy

Why Pasireotide Injection and Alogliptin Interact

The likely mechanism

Altered glucose

How Drug Interactions Work Six short figures, about a minute: how one drug can raise or lower another’s level, or add to or cancel its effect. See how it works 

How to Manage the Pasireotide Injection and Alogliptin Interaction

Your care team can manage this by tailoring your diabetes treatment and watching your blood sugar.

  • If your diabetes is not well controlled, your team may work to improve it before you start pasireotide.
  • Your alogliptin dose may need to be adjusted and individualized by your care team.
  • Your team may have you check your blood sugar more often.
  • Keep taking both medicines as prescribed, and do not change doses on your own.
  • Tell your pharmacist or prescriber about symptoms of low or high blood sugar, or any readings that seem off.

Management is individual — confirm any change with your pharmacist or prescriber.

Questions for Your Pharmacist

  • Does my dose of Pasireotide Injection or Alogliptin need adjusting while I take them together?
  • What symptoms should prompt me to call you or my prescriber right away?
  • Does the timing of my doses matter for this combination?
  • Is there another option that avoids this interaction?

Pasireotide Injection and Alogliptin: Common Questions

How serious is the Pasireotide Injection and Alogliptin interaction?

It is rated major. Potentially serious — often needs a change or close monitoring.

How is the Pasireotide Injection and Alogliptin interaction managed?

Your care team can manage this by tailoring your diabetes treatment and watching your blood sugar. If your diabetes is not well controlled, your team may work to improve it before you start pasireotide. Your alogliptin dose may need to be adjusted and individualized by your care team. Your team may have you check your blood sugar more often. Keep taking both medicines as prescribed, and do not cha… Management is individual — always follow your own care team's guidance.

How quickly could this interaction happen?

The documented onset is "unspecified". The timing of this interaction is not well characterized.

How strong is the evidence for this interaction?

The evidence is graded "theoretical". Expected from how the drugs work, or from studies of similar drugs; this exact pair has little direct study.

Ask About the Pasireotide Injection and Alogliptin Interaction

Ask in your own words about taking Pasireotide Injection and Alogliptin together. The answer comes from this page’s interaction record and both drugs’ own information.

This box answers questions about this one combination only. For anything else about either drug, open its drug information page or ask a pharmacist.

Try:

AI answers from this page’s record and both drugs’ information, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist.

References (5)

  1. Product Information: SIGNIFOR(R) LAR intramuscular injection suspension, pasireotide intramuscular injection suspension. Novartis Pharmaceuticals Corporation (per FDA), East Hanover, NJ, 2014.
  2. Product Information: Sandostatin(R) LAR Depot intramuscular injection suspension, octreotide acetate intramuscular injection suspension. Novartis Pharmaceuticals Corporation (per FDA), East Hanover, NJ, 2014.
  3. Product Information: TOUJEO(R) subcutaneous injection, insulin glargine subcutaneous injection. sanofi-aventis (per manufacturer), Bridgewater, NJ, 2015. DailyMed
  4. Product Information: Tresiba subcutaneous injection solution, insulin degludec subcutaneous injection solution. Novo Nordisk A/S (per EMA), Bagsvaerd, Denmark, 2013. DailyMed
  5. Product Information: ADMELOG(R) subcutaneous, intravenous injection, insulin lispro subcutaneous, intravenous injection. sanofi-aventis US LLC (per DailyMed), Bridgewater, NJ, 2023. DailyMed
Was this write-up helpful?

Other Serious Interactions of Pasireotide Injection and Alogliptin

Also serious with Alogliptin

Also serious with Pasireotide Injection

These Medications Also Interact With Supplements

Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:

With Alogliptin

Check everything you take with our drug–supplement interaction checker.

Still Have Questions About This Combination?

Every question gets a real answer from a licensed pharmacist — free, as soon as they can.

About This Library

Built in-house, documented one interaction at a time. Our interaction database is not a complete list of every known interaction: a combination that isn't listed here hasn't been documented by us yet, which never means it's safe. Checking everything you take at once? Ask your pharmacist to review your full medication list. How we build and review it →

What Each Rating Means

Severity Levels

  • Contraindicated These should generally not be used together.
  • Major Potentially serious — often needs a change or close monitoring. This interaction.
  • Moderate Can be significant — usually manageable with monitoring.
  • Minor Usually limited clinical impact.

Evidence Grades

  • EstablishedWell documented — supported by controlled studies or strong clinical data.
  • ProbableGood supporting evidence, though not definitively proven.
  • SuspectedSome evidence suggests this interaction, but it is not well established.
  • PossibleLimited or conflicting evidence; the interaction may occur.
  • TheoreticalExpected from how the drugs work, or from studies of similar drugs; this exact pair has little direct study. This interaction.

How Soon It Shows

  • RapidEffects can appear quickly, often within about 24 hours of combining the drugs.
  • DelayedEffects tend to build up gradually over days to weeks.
  • UnspecifiedThe timing of this interaction is not well characterized. This interaction.

Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.

Back to the answer
This information is for education, not a substitute for professional medical advice. Do not start, stop, or change any medication without talking to your pharmacist or prescriber.